We use cookies on our website. Carry on browsing if you’re happy with this or find out more



Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy

Kymab's data at the British Society for Immunology Congress demonstrates efficient identification and validation of human antibodies

Three poster presentations at the 2017 British Society for Immunology Congress describe how Kymab's efficient human antibody platforms were able to identify an anti-PD-L1 antibody, KY1003, and show it was an effective anti-tumour antibody in in vitro and in vivo models.

In Rachael Kimber's poster, Cell based screening cascade to select anti-human PD-L1 antibodies, the team describe a cell-based, in vitro screening cascade that enabled functional characterisation of anti-human PD-L 1 antibodies.

They identified a panel of potent fully human, antagonistic antibodies that bind human and cynomolgus PD-L1 and enhance T-cell activity, identifying a lead clone, KY1003, that has the characteristics of a clinically relevant PD-L1 antibody.

Lucy Hepburn presents Development and characterization of a human T cell:tumour cell co-culture assay for assessment of immunomodulatory antibodies, which suggests that prolonged co-culture of human T-cells with the A375 tumour cell line, designed to mimic chronic antigen stimulation, generates T-cells that appear 'exhausted'.

By using these T-cells, the team confirm that Kymab's anti-PD-L1 antibody, KY1003, can enhance in vitro T-cell killing of A375 cells and inhibit immunosuppressive PD-1/PD-L1 signalling to increase tumour elimination by T cells in vivo.

Morgane Lecointre's poster, Development of a "tumour-educated" T cell killing assay for predictive in vitro assessment of anti-PD-L1 antibodies, demonstrates how KY1003 can revert T-cell exhaustion in in vitro models using A375 tumour cells.

Importantly, KY1003 shows a strong anti-tumour efficacy in an in vivo human melanoma xenograft model. The approach is biologically relevant in validation of antibodies that target T-cell immune-modulatory molecules.

Notes to Editors

PDF versions of the posters

British Society for Immunology Congress 2017: http://www.bsicongress.com

British Society for Immunology: https://www.immunology.org

About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.

Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.

Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immuno-oncology, auto-immunity, haematology, infectious disease and other areas.

For more information please see http://www.kymab.com

Kymab is a trademark of Kymab Limited.

Contact information

David Chiswell, Chief Executive Officer

Anne Hyland, Chief Financial Officer

Tel: +44 (0)1223 833 301

Email: anne.hyland@kymab.com

Find out which events we'll be attending this year

View events